What is Palisade Bio Inc (PALI) stock price today?

Palisade Bio Inc (PALI) currently trades at $2.00 per share. The stock has a market capitalization of $328.54M and a P/E ratio of —x.

Is PALI stock a buy, sell, or hold in 2026?

Based on WallStSmart's proprietary analysis, Palisade Bio Inc has a Smart Value Score of 28/100 (Grade F), resulting in a "Strong Sell" investment rating. The Piotroski F-Score is 1/9 and Altman Z-Score is -20.84.

Is Palisade Bio Inc financially healthy?

Palisade Bio Inc's Piotroski F-Score is 1/9 (weak financial health). The Altman Z-Score of -20.84 places it in the distress.

PALI

Palisade Bio Inc

NASDAQ: PALI · HEALTHCARE · BIOTECHNOLOGY

$2.00

+3.63% today

Updated 2026-04-30

Market cap

$328.54M

P/E ratio

—

P/S ratio

11.78x

EPS (TTM)

$-0.30

Dividend yield

—

52W range

$1 – $3

Volume

4.1M

Market cap

$328.54M

P/E ratio

—

P/S ratio

11.78x

EPS (TTM)

$-0.30

Dividend yield

—

52W range

$1 – $3

Volume

4.1M

WallStSmart proprietary scores

out of 100

Grade: F

Strong Sell

Investment rating

4.3

Growth

5.0

Quality

C+

3.0

Profitability

5.0

Valuation

C+

1/9

Piotroski F-Score

Weak

-20.8

Altman Z-Score

Distress

—

Industry rank

—

View all highly rated stocks (75+) →201 stocks currently score above 75

Price targets

Analyst target

$9.71

+385.50%

12-Month target

—

Intrinsic (DCF)

—

Margin of safety

—

2 Strong Buy5 Buy0 Hold0 Sell0 Strong Sell

Price chart

X-Ray snapshot

Strengths

+ Debt/equity 0.07x — low leverage

Risks

- Piotroski 1/9 — weak financial health

- Altman Z -20.84 — distress zone

- Thin margins at 0.00%

- Negative free cash flow $-3.14M

Key financials

Revenue Net Income Free Cash Flow

Metric	2022	2023	2024	2025	TTM
Revenue	$250000.00	$250000.00	$0.00	$0.00	$0.00
Net income	$-14.26M	$-12.30M	$-14.44M	$-16.78M	$-8.90M
EPS	—	—	—	—	$-0.30
Free cash flow	$-13.37M	$-11.14M	$-12.19M	$-10.85M	$-3.14M
Profit margin	-5,704.00%	-4,920.00%	—	—	—

Recent insider activity

Date	Insider	Type	Shares	Price
2026-02-12	JONES, MITCHELL LAWRENCE	Sale	1,989	$1.75
2026-02-12	FINLEY, JOHN DAVID	Sale	3,896	$1.75
2026-02-11	JONES, MITCHELL LAWRENCE	Sale	8,000	—

Peer comparison

Company	Mkt Cap	Score	Growth	Profit	Value	Quality	MoS	Rating
PALI	$328.54M	28	4.3	3.0	5.0	5.0	—	Avoid
LLY	$760.43B	78	10.0	10.0	5.0	6.5	—	Strong Buy
JNJ	$547.28B	59	4.7	9.0	3.3	6.0	-43.54%	Buy
ABBV	$360.63B	63	4.0	8.0	4.7	5.0	-29.31%	Buy
UNH	$322.34B	54	5.3	5.5	7.3	4.8	+42.06%	Buy
AZN	$294.17B	64	6.7	8.0	5.3	5.0	+4.07%	Buy

Smart narrative

Palisade Bio Inc trades at $2.00. Our Smart Value Score of 28/100 indicates the stock is weak. The company scores 1/9 on the Piotroski F-Score. With an Altman Z-Score of -20.84, it sits in the distress.

Frequently asked questions

What is Palisade Bio Inc's stock price?

Palisade Bio Inc (PALI) trades at $2.00.

Is Palisade Bio Inc overvalued?

Smart Value Score 28/100 (Grade F, Strong Sell).

What is the price target of Palisade Bio Inc (PALI)?

The analyst target price is $9.71, representing +385.5% upside from the current price of $2.00.

Piotroski F-Score?

1/9 — weak financial health.

Altman Z-Score?

-20.84 — distress.

Company info

SectorHEALTHCARE

IndustryBIOTECHNOLOGY

CountryUSA

ExchangeNASDAQ

CurrencyUSD

www.palisadebio.com

Quick metrics

P/S ratio11.78x

ROE-24.50%

Beta1.47

50D MA$1.94

200D MA$1.59

Shares out0.17B

Float0.12B

Short ratio—

Avg volume4.1M

Performance

1 week-9.58%

1 month+8.50%

3 months+13.61%

YTD-7.66%

1 year—

3 years—

5 years—

Compare

PALI vs LLY →PALI vs JNJ →PALI vs ABBV →Stock screener →